Testosterone Patent Upheld

[Jinzang]

Endo International staved off generic competition to Aveed, its injectable long-acting testosterone replacement therapy. The ruling means Aveed (testosterone undecanoate) won’t face generic competition until March 14, 2027, when the second of the challenged patents at issue in the litigation expires. Both of the patents cover methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels. Aveed brings in about $11 million a year in U.S. revenues, according to Bloomberg Intelligence analyst Elizabeth Krutoholow. Bayer Healthcare Pharmaceuticals manufactures the drug and has licensed the rights to Endo. Aveed competes with several other testosterone replacement products on the market, including AbbVie’s AndroGel and Eli Lilly’s Axiron, Krutoholow said. Unlike some other testosterone products that are patches or gels, Aveed is implanted under the skin. It’s designed to provide replacement testosterone for up to three months before a patient requires another injection.

Full article available.

 

[Nelson Vergel]

Such dirty game. Abbott did the same with Androgel.

 

[CoastWatcher]

Jinzang, your posts are always worth reading. Thank you.

 

[Vitamin_C]

I know Aveed is popular in Europe but when is it going to be an option in the US?

 

[Jinzang]

I think the only advantage of testosterone undecanoate is for men who don't want to self-inject and would rather have it done in the doctor's office. Otherwise the shorter esters have all the advantages. Because they are quicker acting it's easier to adjust the dose and get dialed in.